The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 524-528

  Kim, Aerang ^a,b   McCully, Cindy ^a   Cruz, Rafael ^a   Cole, Diane E ^a   Fox, Elizabeth ^a,c   Balis, Frank M ^a,c   Widemann, Brigitte C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Cerebrospinal fluid; Non human primate model; Pharmacokinetics; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ADULT ANIMAL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MACACA MULATTA; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANIMAL MODEL; BIOLOGICAL MODEL; BLOOD; BLOOD BRAIN BARRIER; CAPILLARY PERMEABILITY; CEREBROSPINAL FLUID; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; PROTEIN BINDING;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BENZENESULFONATES; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; INFUSIONS, INTRAVENOUS; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; MODELS, ANIMAL; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIDINES; TANDEM MASS SPECTROMETRY;

EID: 84862268482     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9585-1     Document Type: Article

References (30)

1. Wilhelm SM et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099-7109
2. Lowy DR, Willumsen BM (1993) Function and regulation of ras. Annu Rev Biochem 62:851-891
3. Rodenhuis S (1992) Ras and human tumors. Semin Cancer Biol 3 (4):241-247
4. Satoh T, Kaziro Y (1992) Ras in signal transduction. Semin Cancer Biol 3(4):169-177
5. Reuter CW, Morgan MA, Bergmann L (2000) Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 96(5):1655-1669
6. Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653(1):25-40
7. Minniti G et al (2009) Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 29(12):5171-5184
8. Newton HB (2007) Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Curr Opin Investig Drugs 8(12):1009-1021
9. Forshew T et al (2009) Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 218(2):172-181
10. Tatevossian RG et al (2010) MAPK pathway activation and the origins of pediatric low-grade astrocytomas. J Cell Physiol 222(3):509-514
11. Jain RK et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610-622
12. Machein MR, Plate KH (2000) VEGF in brain tumors. J Neurooncol 50(1-2):109-120
13. Jane EP, Premkumar DR, Pollack IF (2006) Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 319(3):1070-1080
14. Yang F et al (2008) Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 7(11):3519-3526
15. McCully CL et al (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40 (5):520-525
16. Freireich EJ et al (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50(4):219-244
17. Jain L et al (2008) Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 46(2):362-367
18. Administration, U.D.o.H.a.H.S.F.a.D., Guidance for Industry, Bioanalytical Method Validation. May 2001
19. Nexavar (sorafenib) package insert. 2005: West Haven, CT
20. Strumberg D et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12 (4):426-437
21. Widemann B et al (2009) Phase I study of sorafenib in children with refractory solid tumors: a children's oncology group phase I consortium trial. J Clin Oncol 27(15s): p. Suppl; abstr 10012
22. Strumberg D et al (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23(5):965-972
23. Awada A et al (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92 (10):1855-1861
24. Moore M et al (2005) Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 16(10):1688-1694
25. Clark JW et al (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11(15):5472-5480
26. Jacobs S et al. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 65(5): 817-824
27. Fox E et al (2002) Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther 301(3):1003-1011
28. Valcamonico F et al (2009) Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma. J Neurooncol 91(1):47-50
29. Massard C et al (2010) Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 21(5):1247-1254
30. Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125-134